| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for IPN from our risk checks.
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €106.40 |
| 52 Week High | €130.70 |
| 52 Week Low | €99.70 |
| Beta | 0.64 |
| 1 Month Change | 1.14% |
| 3 Month Change | 1.04% |
| 1 Year Change | 0.57% |
| 3 Year Change | 33.23% |
| 5 Year Change | -7.56% |
| Change since IPO | 348.95% |
Recent News & Updates
There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price
Apr 13
Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly
Mar 26Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)
Dec 30Recent updates
There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price
Apr 13Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly
Mar 26Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)
Dec 30These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well
Dec 11Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?
Sep 28These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well
Sep 07Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?
Jun 21Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20
Jun 02Ipsen's (EPA:IPN) Dividend Will Be €1.20
May 12Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate
Mar 19Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet
Mar 01Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth
Jan 19Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?
Dec 08We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease
Nov 02Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?
Oct 14Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?
Aug 01Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today
Jul 10Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20
May 26Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20
May 04Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20
Apr 19Is Ipsen (EPA:IPN) A Risky Investment?
Apr 18Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today
Mar 18Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?
Feb 14Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet
Nov 04We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease
Aug 05Ipsen S.A. (EPA:IPN) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 15Shareholder Returns
| IPN | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -2.7% | -2.0% | -0.4% |
| 1Y | 0.6% | -14.0% | 1.7% |
Return vs Industry: IPN exceeded the French Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: IPN underperformed the French Market which returned 1.7% over the past year.
Price Volatility
| IPN volatility | |
|---|---|
| IPN Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: IPN has not had significant price volatility in the past 3 months.
Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
| IPN fundamental statistics | |
|---|---|
| Market cap | €8.79b |
| Earnings (TTM) | €617.10m |
| Revenue (TTM) | €3.31b |
14.2x
P/E Ratio2.7x
P/S RatioIs IPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPN income statement (TTM) | |
|---|---|
| Revenue | €3.31b |
| Cost of Revenue | €571.20m |
| Gross Profit | €2.74b |
| Other Expenses | €2.12b |
| Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 24, 2024
| Earnings per share (EPS) | 7.47 |
| Gross Margin | 82.72% |
| Net Profit Margin | 18.66% |
| Debt/Equity Ratio | 9.6% |
How did IPN perform over the long term?
See historical performance and comparison